Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Objective of this study is to investigate of efficacy and safety of recombinant adenoviral
human p53 Gene (rAd-p53) in treatment of malignant pleural effusion, compared to cisplatin.
This is a phase 2, double blinded, randomized, active controlled study.